Pfizer has announced that its mini-dystrophin gene therapy has not met its primary or secondary endpoints.
Click here to read Pfizer’s update on Phase 3 of CIFFREO, a randomised double-blind placebo-controlled study in ambulatory boys aged 4-7.
The primary endpoint was improved motor function and assessed by a change in the North Star Ambulatory Assessment one year after treatment, while secondary endpoints included measuring the 10 metre run/walk velocity and time to rise from floor velocity.
The pharmaceutical company has expressed its disappointment in the results, and has said it will continue to monitor all participants enrolled in the study, with further results to be shared at upcoming patient and medical advocacy meetings.